Population pharmacokinetics model and initial dose optimization of tacrolimus in children and adolescents with lupus nephritis based on real‑world data
- Authors:
- Xiao Chen
- Dong‑Dong Wang
- Hong Xu
- Zhi‑Ping Li
-
Affiliations: Department of Pharmacy, Children's Hospital of Fudan University, Shanghai 201102, P.R. China, Department of Nephrology, Children's Hospital of Fudan University, Shanghai 201102, P.R. China - Published online on: May 30, 2020 https://doi.org/10.3892/etm.2020.8821
- Pages: 1423-1430
-
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
|
Papadimitraki ED and Isenberg DA: Childhood- and adult-onset lupus: An update of similarities and differences. Expert Rev Clin Immunol. 5:391–403. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Takeuchi T, Tsuzaka K, Abe T, Yoshimoto K, Shiraishi K, Kameda H and Amano K: T cell abnormalities in systemic lupus erythematosus. Autoimmunity. 38:339–346. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Rahman A and Isenberg DA: Systemic lupus erythematosus. N Engl J Med. 358:929–939. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Gurevitz SL, Snyder JA, Wessel EK, Frey J and Williamson BA: Systemic lupus erythematosus: A review of the disease and treatment options. Consult Pharm. 28:110–121. 2013.PubMed/NCBI View Article : Google Scholar | |
|
D'Cruz DP, Khamashta MA and Hughes GR: Systemic lupus erythematosus. Lancet. 369:587–596. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Huang JL, Yeh KW, Yao TC, Huang YL, Chung HT, Ou LS, Lee WI and Chen LC: Pediatric lupus in Asia. Lupus. 19:1414–1418. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Tanaka H, Joh K and Imaizumi T: Treatment of pediatric-onset lupus nephritis: A proposal of optimal therapy. Clin Exp Nephrol. 21:755–763. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Takei S, Maeno N, Shigemori M, Imanaka H, Mori H, Nerome Y, Kanekura S, Takezaki T, Hokonohara M, Miyata K and Fujikawa S: Clinical features of Japanese children and adolescents with systemic lupus erythematosus: Results of 1980-1994 survey. Acta Paediatr Jpn. 39:250–256. 1997.PubMed/NCBI View Article : Google Scholar | |
|
Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, Boletis J, Cervera R, Dörner T, Doria A, et al: Joint European league against rheumatism and European renal association-European dialysis and transplant association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 71:1771–1782. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Zhou T, Lin S, Yang S and Lin W: Efficacy and safety of tacrolimus in induction therapy of patients with lupus nephritis. Drug Des Devel Ther. 13:857–869. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Vadcharavivad S, Praisuwan S, Techawathanawanna N, Treyaprasert W and Avihingsanon Y: Population pharmacokinetics of tacrolimus in Thai kidney transplant patients: Comparison with similar data from other populations. J Clin Pharm Ther. 41:310–328. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Wang D, Chen X, Xu H and Li Z: Population pharmacokinetics and dosing regimen optimization of tacrolimus in Chinese pediatric hematopoietic stem cell transplantation patients. Xenobiotica. 50:178–185. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Wang DD, Lu JM, Li Q and Li ZP: Population pharmacokinetics of tacrolimus in paediatric systemic lupus erythematosus based on real-world study. J Clin Pharm Ther. 43:476–483. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Chen X, Wang D, Xu H and Li Z: Initial dose optimization of tacrolimus for children with systemic lupus erythematosus based on the CYP3A5 polymorphism and coadministration with Wuzhi capsule. J Clin Pharm Ther. 45:309–317. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Mizuno T, Fukuda T, Christians U, Perentesis JP, Fouladi M and Vinks AA: Population pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumours: A report from the Children's Oncology Group. Br J Clin Pharmacol. 83:1097–1107. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Yang JW, Liao SS, Zhu LQ, Zhao Y, Zhang Y, Sun XY, Rao W, Qu W, Li WZ and Sun LY: Population pharmacokinetic analysis of tacrolimus early after Chinese pediatric liver transplantation. Int J Clin Pharmacol Ther. 53:75–83. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Lindbom L, Pihlgren P and Jonsson EN: PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 79:241–257. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Jusko WJ, Piekoszewski W, Klintmalm GB, Shaefer MS, Hebert MF, Piergies AA, Lee CC, Schechter P and Mekki QA: Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther. 57:281–290. 1995.PubMed/NCBI View Article : Google Scholar | |
|
Anderson BJ and Holford NH: Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 48:303–332. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Ho S, Clipstone N, Timmermann L, Northrop J, Graef I, Fiorentino D, Nourse J and Crabtree GR: The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol. 80:S40–S45. 1996.PubMed/NCBI View Article : Google Scholar | |
|
Wang DD, Chen X and Li ZP: Tacrolimus ameliorates proteinuria in Chinese pediatric lupus nephritis patients. Int J Clin Exp Med. 12:10931–10937. 2019. | |
|
Andreu F, Colom H, Grinyo JM, Torras J, Cruzado JM and Lloberas N: Development of a population PK model of tacrolimus for adaptive dosage control in stable kidney transplant patients. Ther Drug Monit. 37:246–255. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Benkali K, Rostaing L, Premaud A, Woillard JB, Saint-Marcoux F, Urien S, Kamar N, Marquet P and Rousseau A: Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation. Clin Pharmacokinet. 49:683–692. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Bergmann TK, Hennig S, Barraclough KA, Isbel NM and Staatz CE: Population pharmacokinetics of tacrolimus in adult kidney transplant patients: Impact of CYP3A5 genotype on starting dose. Ther Drug Monit. 36:62–70. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Han N, Ha S, Yun HY, Kim MG, Min SI, Ha J, Lee JI, Oh JM and Kim IW: Population pharmacokinetic-pharmacogenetic model of tacrolimus in the early period after kidney transplantation. Basic Clin Pharmacol Toxicol. 114:400–406. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Zhao W, Elie V, Roussey G, Brochard K, Niaudet P, Leroy V, Loirat C, Cochat P, Cloarec S, André JL, et al: Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. Clin Pharmacol Ther. 86:609–618. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Zuo XC, Ng CM, Barrett JS, Luo AJ, Zhang BK, Deng CH, Xi LY, Cheng K, Ming YZ, Yang GP, et al: Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: A population pharmacokinetic analysis. Pharmacogenet Genomics. 23:251–261. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Lu YX, Su QH, Wu KH, Ren YP, Li L, Zhou TY and Lu W: A population pharmacokinetic study of tacrolimus in healthy Chinese volunteers and liver transplant patients. Acta Pharmacol Sin. 36:281–288. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Musuamba FT, Guy-Viterbo V, Reding R, Verbeeck RK and Wallemacq P: Population pharmacokinetic analysis of tacrolimus early after pediatric liver transplantation. Ther Drug Monit. 36:54–61. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Wallin JE, Bergstrand M, Wilczek HE, Nydert PS, Karlsson MO and Staatz CE: Population pharmacokinetics of tacrolimus in pediatric liver transplantation: Early posttransplantation clearance. Ther Drug Monit. 33:663–672. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Zhang XQ, Wang ZW, Fan JW, Li YP, Jiao Z, Gao JW, Peng ZH and Liu GL: The impact of sulfonylureas on tacrolimus apparent clearance revealed by a population pharmacokinetics analysis in Chinese adult liver-transplant patients. Ther Drug Monit. 34:126–133. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Zhu L, Yang J, Zhang Y, Jing Y, Zhang Y and Li G: Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T/A polymorphism on pharmacokinetics of Tacrolimus in Chinese adult liver transplant patients. Xenobiotica. 45:840–846. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Wang DD, Chen X, Fu M, Zheng QS, Xu H and Li ZP: Model extrapolation to a real-world dataset: Evaluation of tacrolimus population pharmacokinetics and drug interaction in pediatric liver transplantation patients. Xenobiotica. 50:371–379. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Wang DD, Chen X and Li ZP: Wuzhi capsule and haemoglobin influence tacrolimus elimination in paediatric kidney transplantation patients in a population pharmacokinetics analysis: A retrospective study. J Clin Pharm Ther. 44:611–617. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Fay JW, Nash RA, Wingard JR, Przepiorka D, Collins RH, Anasetti C, Devine SM, Pineiro LA, Storb RF, Aro RM, et al: FK 506-based immunosuppression for prevention of graft versus host disease after unrelated donor marrow transplantation. Transplant Proc. 27(1374)1995.PubMed/NCBI | |
|
Fay JW, Wingard JR, Antin JH, Collins RH, Piñeiro LA, Blazar BR, Saral R, Bierer BE, Przepiorka D, Fitzsimmons WE, et al: FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation. Blood. 87:3514–3519. 1996.PubMed/NCBI | |
|
Nash RA, Etzioni R, Storb R, Furlong T, Gooley T, Anasetti C, Appelbaum FR, Doney K, Martin P, Slattery J, et al: Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: A single-center study. Blood. 85:3746–3753. 1995.PubMed/NCBI | |
|
Nash RA, Piñeiro LA, Storb R, Deeg HJ, Fitzsimmons WE, Furlong T, Hansen JA, Gooley T, Maher RM, Martin P, et al: FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. Blood. 88:3634–3641. 1996.PubMed/NCBI | |
|
Przepiorka D, Ippoliti C, Khouri I, Woo M, Mehra R, Le Bherz D, Giralt S, Gajewski J, Fischer H, Fritsche H, et al: Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. Blood. 88:4383–4389. 1996.PubMed/NCBI | |
|
Uberti JP, Silver SM, Adams PT, Jacobson P, Scalzo A and Ratanatharathorn V: Tacrolimus and methotrexate for the prophylaxis of acute graft-versus-host disease in allogeneic bone marrow transplantation in patients with hematologic malignancies. Bone Marrow Transplant. 19:1233–1238. 1997.PubMed/NCBI View Article : Google Scholar | |
|
Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM, Przepiorka D, Davies S, Petersen FB, Bartels P, et al: Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood. 96:2062–2068. 2000.PubMed/NCBI | |
|
Wang D, Chen X, Xu H and Li Z: Population pharmacokinetics and dosing regimen optimisation of tacrolimus in Chinese pediatric hematopoietic stem cell transplantation patients. Xenobiotica. 50:178–185. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Monchaud C, de Winter BC, Knoop C, Estenne M, Reynaud-Gaubert M, Pison C, Stern M, Kessler R, Guillemain R, Marquet P and Rousseau A: Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation. Clin Pharmacokinet. 51:175–186. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Han Y, Zhou H, Cai J, Huang J, Zhang J, Shi SJ, Liu YN and Zhang Y: Prediction of tacrolimus dosage in the early period after heart transplantation: A population pharmacokinetic approach. Pharmacogenomics. 20:21–35. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Chandrasekhara PK, Jayachandran NV, Thomas J, Agrawal S and Narsimulu G: Successful treatment of pyoderma gangrenosum associated with juvenile idiopathic arthritis with a combination of topical tacrolimus and oral prednisolone. Clin Rheumatol. 28:489–490. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Shimizu M, Ueno K, Ishikawa S, Tokuhisa Y, Inoue N and Yachie A: Treatment of refractory polyarticular juvenile idiopathic arthritis with tacrolimus. Rheumatology (Oxford). 53:2120–2122. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Tanaka H, Tsugawa K, Suzuki K, Oki ES, Nonaka K, Kimura S and Ito E: Treatment of difficult cases of systemic-onset juvenile idiopathic arthritis with tacrolimus. Eur J Pediatr. 166:1053–1055. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Wang D, Chen X and Li Z: Treatment of patients with systemic-onset juvenile idiopathic arthritis with tacrolimus. Exp Ther Med. 17:2305–2309. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Choudhry S, Bagga A, Hari P, Sharma S, Kalaivani M and Dinda A: Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: A randomized controlled trial. Am J Kidney Dis. 53:760–769. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Gulati A, Sinha A, Gupta A, Kanitkar M, Sreenivas V, Sharma J, Mantan M, Agarwal I, Dinda AK, Hari P and Bagga A: Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome. Kidney Int. 82:1130–1135. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Gulati S, Prasad N, Sharma RK, Kumar A, Gupta A and Baburaj VP: Tacrolimus: A new therapy for steroid-resistant nephrotic syndrome in children. Nephrol Dial Transplant. 23:910–913. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Loeffler K, Gowrishankar M and Yiu V: Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome. Pediatr Nephrol. 19:281–287. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Roberti I and Vyas S: Long-term outcome of children with steroid-resistant nephrotic syndrome treated with tacrolimus. Pediatr Nephrol. 25:1117–1124. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Yang EM, Lee ST, Choi HJ, Cho HY, Lee JH, Kang HG, Park YS, Cheong HI and Ha IS: Tacrolimus for children with refractory nephrotic syndrome: A one-year prospective, multicenter, and open-label study of Tacrobell(R), a generic formula. World J Pediatr. 12:60–65. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Wang D, Lu J, Li Q and Li Z: Population pharmacokinetics of tacrolimus in pediatric refractory nephrotic syndrome and a summary of other pediatric disease models. Exp Ther Med. 17:4023–4031. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Duddridge M and Powell RJ: Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases. Ann Rheum Dis. 56:690–692. 1997.PubMed/NCBI View Article : Google Scholar | |
|
Miyasaka N, Kawai S and Hashimoto H: Efficacy and safety of tacrolimus for lupus nephritis: A placebo-controlled double-blind multicenter study. Mod Rheumatol. 19:606–615. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Watanabe H, Yamanaka R, Sada KE, Zeggar S, Katsuyama E, Katsuyama T, Narazaki MT, Tatebe NT, Sugiyama K, Watanabe KS, et al: The efficacy of add-on tacrolimus for minor flare in patients with systemic lupus erythematosus: A retrospective study. Lupus. 25:54–60. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Yoon KH: Efficacy and cytokine modulating effects of tacrolimus in systemic lupus erythematosus: A review. J Biomed Biotechnol. 2010(686480)2010.PubMed/NCBI View Article : Google Scholar | |
|
Szeto CC, Kwan BC, Lai FM, Tam LS, Li EK, Chow KM, Gang W and Li PK: Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology (Oxford). 47:1678–1681. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Kusunoki Y, Tanaka N, Kaneko K, Yamamoto T, Endo H and Kawai S: Tacrolimus therapy for systemic lupus erythematosus without renal involvement: A preliminary retrospective study. Mod Rheumatol. 19:616–621. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Alsuwaida A: Successful management of systemic lupus erythematosus nephritis flare-up during pregnancy with tacrolimus. Mod Rheumatol. 21:73–75. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Li H, Zhang X and Chen J: Successful treatment of steroid-refractory systemic lupus erythematosus-associated protein-losing enteropathy using combination therapy with tacrolimus and steroid. Lupus. 20:1109–1111. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Kaieda S, Kobayashi T, Moroki M, Honda S, Yuge K, Kawano H, Mitsuyama K, Sata M, Ida H, Hoshino T and Fukuda T: Successful treatment of rectal ulcers in a patient with systemic lupus erythematosus using corticosteroids and tacrolimus. Mod Rheumatol. 24:357–360. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Politt D, Heintz B, Floege J and Mertens PR: Tacrolimus-(FK 506) based immunosuppression in severe systemic lupus erythematosus. Clin Nephrol. 62:49–53. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Zhang Z, Yang C, Zhang L, Yi Q and Hao Z: Efficacy and safety of tacrolimus in myasthenia gravis: A systematic review and meta-analysis. Ann Indian Acad Neurol. 20:341–347. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Wang L, Zhang S, Xi J, Li W, Zhou L, Lu J, Lu J, Zhang T and Zhao C: Efficacy and safety of tacrolimus for myasthenia gravis: A systematic review and meta-analysis. J Neurol. 264:2191–2200. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Komaki Y, Komaki F, Ido A and Sakuraba A: Efficacy and safety of tacrolimus therapy for active ulcerative colitis; A systematic review and meta-analysis. J Crohns Colitis. 10:484–494. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Matsuoka K, Saito E, Fujii T, Takenaka K, Kimura M, Nagahori M, Ohtsuka K and Watanabe M: Tacrolimus for the treatment of ulcerative colitis. Intest Res. 13:219–226. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Hanouneh M, Ritchie MM, Ascha M, Ascha MS, Chedid A, Sanguankeo A, Zein NN and Hanouneh IA: A review of the utility of tacrolimus in the management of adults with autoimmune hepatitis. Scand J Gastroenterol. 54:76–80. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Scott LJ, McKeage K, Keam SJ and Plosker GL: Tacrolimus: A further update of its use in the management of organ transplantation. Drugs. 63:1247–1297. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Naesens M, Kuypers DR and Sarwal M: Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 4:481–508. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Entani C, Izumino K, Iida H, Fujita M, Asaka M, Takata M and Sasayama S: Effect of a novel immunosuppressant, FK506, on spontaneous lupus nephritis in MRL/MpJ-lpr/lpr mice. Nephron. 64:471–475. 1993.PubMed/NCBI View Article : Google Scholar | |
|
Jusko WJ, Thomson AW, Fung J, McMaster P, Wong SH, Zylber-Katz E, Christians U, Winkler M, Fitzsimmons WE, Lieberman R, et al: Consensus document: Therapeutic monitoring of tacrolimus (FK-506). Ther Drug Monit. 17:606–614. 1995.PubMed/NCBI View Article : Google Scholar | |
|
Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, McMichael J, Lever J, Burckart G and Starzl T: Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet. 29:404–430. 1995.PubMed/NCBI View Article : Google Scholar | |
|
Zheng QS and Li LJ: Pharmacometrics: A quantitative tool of pharmacological research. Acta Pharmacol Sin. 33:1337–1338. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Chen CY, Zhou Y, Cui YM, Yang T, Zhao X and Wu Y: Population pharmacokinetics and dose simulation of oxcarbazepine in Chinese paediatric patients with epilepsy. J Clin Pharm Ther. 44:300–311. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Chen Y, Wu D, Dong M, Zhu Y, Lu J, Li X, Chen C and Li Z: Population pharmacokinetics of vancomycin and AUC-guided dosing in Chinese neonates and young infants. Eur J Clin Pharmacol. 74:921–930. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Zheng Y, Liu SP, Xu BP, Shi ZR, Wang K, Yang JB, Huang X, Tang BH, Chen XK, Shi HY, et al: Population pharmacokinetics and dosing optimization of azithromycin in children with community-acquired pneumonia. Antimicrob Agents Chemother. 62(e00686-18)2018.PubMed/NCBI View Article : Google Scholar | |
|
Wang DD, Ye QF, Chen X, Xu H and Li ZP: Population pharmacokinetics and initial dosing regimen optimization of cyclosporin in pediatric hemophagocytic lymphohistiocytosis patients. Xenobiotica. 50:435–441. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Lu T, Zhu X, Xu S, Zhao M, Huang X, Wang Z and Zhao L: Dosage optimization based on population pharmacokinetic analysis of tacrolimus in chinese patients with nephrotic syndrome. Pharm Res. 36(45)2019.PubMed/NCBI View Article : Google Scholar | |
|
Wang X, Han Y, Chen C, Ma L, Xiao H, Zhou Y, Cui Y, Wang F, Su B, Yao Y and Ding J: Population pharmacokinetics and dosage optimization of tacrolimus in pediatric patients with nephrotic syndrome. Int J Clin Pharmacol Ther. 57:125–134. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Wei H, Tao X, Di P, Yang Y, Li J, Qian X, Feng J and Chen W: Effects of traditional chinese medicine Wuzhi capsule on pharmacokinetics of tacrolimus in rats. Drug Metab Dispos. 41:1398–1403. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Xin HW, Li Q, Wu XC, He Y, Yu AR, Xiong L and Xiong Y: Effects of Schisandra sphenanthera extract on the blood concentration of tacrolimus in renal transplant recipients. Eur J Clin Pharmacol. 67:1309–1311. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Xin HW, Wu XC, Li Q, Yu AR, Zhu M, Shen Y, Su D and Xiong L: Effects of Schisandra sphenanthera extract on the pharmacokinetics of tacrolimus in healthy volunteers. Br J Clin Pharmacol. 64:469–475. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Qin XL, Bi HC, Wang CX, Li JL, Wang XD, Liu LS, Chen X and Huang M: Study of the effect of Wuzhi tablet (Schisandra sphenanthera extract) on tacrolimus tissue distribution in rat by liquid chromatography tandem mass spectrometry method. Biomed Chromatogr. 24:399–405. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Qin XL, Bi HC, Wang XD, Li JL, Wang Y, Xue XP, Chen X, Wang CX, Xu le J, Wang YT and Huang M: Mechanistic understanding of the different effects of Wuzhi Tablet (Schisandra sphenanthera extract) on the absorption and first-pass intestinal and hepatic metabolism of Tacrolimus (FK506). Int J Pharm. 389:114–121. 2010.PubMed/NCBI View Article : Google Scholar |
